Your browser doesn't support javascript.
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.
Drake, Thomas M; Docherty, Annemarie B; Harrison, Ewen M; Quint, Jennifer K; Adamali, Huzaifa; Agnew, Sarah; Babu, Suresh; Barber, Christopher M; Barratt, Shaney; Bendstrup, Elisabeth; Bianchi, Stephen; Villegas, Diego Castillo; Chaudhuri, Nazia; Chua, Felix; Coker, Robina; Chang, William; Crawshaw, Anjali; Crowley, Louise E; Dosanjh, Davinder; Fiddler, Christine A; Forrest, Ian A; George, Peter M; Gibbons, Michael A; Groom, Katherine; Haney, Sarah; Hart, Simon P; Heiden, Emily; Henry, Michael; Ho, Ling-Pei; Hoyles, Rachel K; Hutchinson, John; Hurley, Killian; Jones, Mark; Jones, Steve; Kokosi, Maria; Kreuter, Michael; MacKay, Laura S; Mahendran, Siva; Margaritopoulos, George; Molina-Molina, Maria; Molyneaux, Philip L; O'Brien, Aiden; O'Reilly, Katherine; Packham, Alice; Parfrey, Helen; Poletti, Venerino; Porter, Joanna C; Renzoni, Elisabetta; Rivera-Ortega, Pilar; Russell, Anne-Marie.
  • Drake TM; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Docherty AB; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Harrison EM; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Quint JK; National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Adamali H; Bristol Interstitial Lung Disease Service, North Bristol NHS Trust and.
  • Agnew S; Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, United Kingdom.
  • Babu S; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
  • Barber CM; Queen Alexandra Hospital, Portsmouth, United Kingdom.
  • Barratt S; Northern General Hospital, Sheffield, United Kingdom.
  • Bendstrup E; Bristol Interstitial Lung Disease Service, North Bristol NHS Trust and.
  • Bianchi S; Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, United Kingdom.
  • Villegas DC; Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
  • Chaudhuri N; Northern General Hospital, Sheffield, United Kingdom.
  • Chua F; Interstitial Lung Disease (ILD) Unit, Respiratory Medicine Department, Hospital of the Holy Cross and Saint Paul, Barcelona, Spain.
  • Coker R; ILD Unit, Manchester University Hospital NHS Foundation Trust, Wythenshawe Hospital, Wythenshawe, United Kingdom.
  • Chang W; University of Manchester, Manchester, United Kingdom.
  • Crawshaw A; Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
  • Crowley LE; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Dosanjh D; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
  • Fiddler CA; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Forrest IA; University of Birmingham, Birmingham, United Kingdom.
  • George PM; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Gibbons MA; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.
  • Groom K; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
  • Haney S; National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Hart SP; Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
  • Heiden E; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust, Exeter, United Kingdom.
  • Henry M; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Ho LP; Northumbria Specialist Emergency Care Hospital, Northumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom.
  • Hoyles RK; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, United Kingdom.
  • Hutchinson J; University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Hurley K; Cork University Hospital, Cork, Ireland.
  • Jones M; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Jones S; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Kokosi M; King's Mill Hospital, Nottinghamshire, United Kingdom.
  • Kreuter M; Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • MacKay LS; Beaumont Hospital, Dublin, Ireland.
  • Mahendran S; University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Margaritopoulos G; National Institute for Health Research (NIHR) Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.
  • Molina-Molina M; Action for Pulmonary Fibrosis, Stuart House, Peterborough, United Kingdom.
  • Molyneaux PL; Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
  • O'Brien A; Guys and St. Thomas' NHS Trust, London, United Kingdom.
  • O'Reilly K; Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg and German Center for Lung Research, Heidelberg, Germany.
  • Packham A; Northumbria Specialist Emergency Care Hospital, Northumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom.
  • Parfrey H; Kingston Hospital NHS Foundation Trust, Surrey, United Kingdom.
  • Poletti V; ILD Unit, Manchester University Hospital NHS Foundation Trust, Wythenshawe Hospital, Wythenshawe, United Kingdom.
  • Porter JC; ILD Unit, Respiratory Department, University Hospital of Bellvitge, Institut d'Investigació Biomèdica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
  • Renzoni E; National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Rivera-Ortega P; University Hospital Limerick, Limerick, Ireland.
  • Russell AM; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Am J Respir Crit Care Med ; 202(12): 1656-1665, 2020 12 15.
Article in English | MEDLINE | ID: covidwho-810560
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Rationale The impact of coronavirus disease (COVID-19) on patients with interstitial lung disease (ILD) has not been established.

Objectives:

To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporaneous age-, sex-, and comorbidity-matched population.

Methods:

An international multicenter audit of patients with a prior diagnosis of ILD admitted to the hospital with COVID-19 between March 1 and May 1, 2020, was undertaken and compared with patients without ILD, obtained from the ISARIC4C (International Severe Acute Respiratory and Emerging Infection Consortium Coronavirus Clinical Characterisation Consortium) cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished idiopathic pulmonary fibrosis from non-idiopathic pulmonary fibrosis ILD and used lung function to determine the greatest risks of death.Measurements and Main

Results:

Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to the hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching, patients with ILD with COVID-19 had significantly poorer survival (hazard ratio [HR], 1.60; confidence interval, 1.17-2.18; P = 0.003) than age-, sex-, and comorbidity-matched controls without ILD. Patients with an FVC of <80% had an increased risk of death versus patients with FVC ≥80% (HR, 1.72; 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR, 2.27; 1.39-3.71).

Conclusions:

Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Diseases, Interstitial / COVID-19 / Hospitalization Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Am J Respir Crit Care Med Journal subject: Critical Care Year: 2020 Document Type: Article Affiliation country: Rccm.202007-2794OC

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Diseases, Interstitial / COVID-19 / Hospitalization Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Am J Respir Crit Care Med Journal subject: Critical Care Year: 2020 Document Type: Article Affiliation country: Rccm.202007-2794OC